News

New NHS statistics show an increase in uptake for the first time in five years.

Back in February, the purchase hit a significant obstacle after BMS’ largest institutional shareholder – Wellington Management – said it did not back the deal.

The company was initially formed in 2017 off the back of research by Professor Jason Carroll, whose scientific insights have led to a new approach to target FOXA1 driven cancer.

The MSD blockbuster has been approved as monotherapy or as part of a chemotherapy combination.

GSK’s formulation of the drug, Zantac, was recalled in the USA last month after the FDA found “unacceptable” levels of carcinogen in the medicine.

96.7% of men in the relugolix trial achieved sustained testosterone suppression to castrate levels.

The four-hour workshop will educate students aged seven to 13 on heart health.

The money will go towards the development of the new “Spark Building”, which will provide interim lab and office accommodation whilst more permanent accommodation is developed nearby.

The Phase II trial results are “impressive” and “encouraging”.

76% of health leaders said in a survey that supporting and growing the NHS workforce should be a critical priority, ranking it highest.

The Invokana trial will be completed virtually, with no in-person clinical visits required.

Co-administered with aspirin, Brilinta is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndrome.

The funding announcement coincides with the launch of Cancer Research UK’s “Right Now” campaign, which aims to show both the realities of the disease and the positive impact research and improved treatments can have on people’s lives.

As of the approval, the treatment is expected to be available to patients in the coming weeks.